DxS Ltd
DxS Ltd
复制标题
DOI：
10.2217/14622416.9.4.463
复制
发表时间：
2008-04-01
期刊：
影响因子：
2.1
通讯作者：
Cross, Joanne
中科院分区：
文献类型：
--
作者：
Cross, Joanne
DxS是一家个性化医药公司，满足制药行业对生物标志物和伴随诊断的需求，以支持癌症和其他疗法的开发和销售。该公司提供主要用于临床试验的生物标志物产品和辅助诊断产品，帮助医生为患者选择治疗方法。DxS与制药公司合作，通过识别药物治疗的可能反应者，提供经过验证的生物标志物检测，以支持药物开发和监管批准。DxS推出了世界上第一个癌症突变伴随诊断，以支持安进公司的Vectibix（TM）结肠直肠癌治疗。DxS试剂盒检测与癌症药物反应相关的癌基因突变。TheraScreen（R）是一系列CE认证的诊断产品，用于检测EGFR和K-RAS基因的突变。经验证的生物标志物试剂盒可用于EGFR、RAS、RAF BCR-ABL和其他显示患者突变状态与药物应答之间相关性的基因的研究。
DxS is a personalized medicine company that meets the needs of the pharmaceutical industry for biomarkers and companion diagnostics to support the development and sales of cancer and other therapies. The company provides both biomarker products, which are used predominately during clinical trials, and companion diagnostics, which aid doctors in selecting therapies for patients. Working in partnership with drug companies, DxS offer validated biomarker assays to support drug development and then regulatory approval, by identifying likely responders to drug therapies. DxS have launched the world's first cancer mutation companion diagnostic to support Amgen's Vectibix (TM) colorectal cancer therapy. DxS kits detect mutations in oncogenes associated with cancer drug response. TheraScreen (R) is the range of CE-marked diagnostic products for detecting mutations in the EGFR and K-RAS genes. Validated biomarker kits are available for research use for EGFR, RAS, RAF BCR-ABL and other genes that show a correlation between patient mutation status and drug response.